Despite potent antibiotics, gram-negative bacteremia and sepsis remain a frequent cause of death among hospitalized patients (33, 34) . Escherichia coli strains are most frequently isolated from these patients (12, 19) . The development of protective antibodies for passive immunization against gramnegative bacteria in general and E. coli in particular is therefore an important objective. Lipopolysaccharide (LPS), a constituent of the outer membrane of gram-negative bacteria, consists of lipid A (the toxic moiety of LPS), a relatively conserved core oligosaccharide, and a terminal polysaccharide of variable length and composition that comprises the O-antigenspecific domain. Effort has been invested in the development of monoclonal antibodies (MAbs) against lipid A, the toxic moiety of LPS (endotoxin), which is highly conserved among gram-negative bacteria. In contrast to capsules and O antigens, lipid A is not highly variable, and cross-reactive lipid A antibodies have been demonstrated. So far, however, no conclusive data which show a protective activity of these cross-reactive antibodies in patients have been obtained (13, 35) . Therefore, it may be worthwhile to develop MAbs against the capsules and O antigens of the most prevalent virulent strains of E. coli. Such MAbs have proven to be protective in animal models (7, 23, 25, 28) . Enhanced protection by the combination of anti-K1 and anti-O18 MAbs against E. coli O18K1 has been described (17) . However, the mechanism of the additional protection has not been elucidated.
In this study, we observed a similar enhanced protection for the combination of anticapsule and anti-O MAbs for E. coli O18K5. The O18 antigen is one of the four most prevalent O antigens of E. coli strains isolated from bacteremic patients (3, 10, 18) . The immunogenicity of the K5 capsule is relatively low, which might be due to the similarity of the capsular polysaccharide and the host carbohydrates (6, 15) . Therefore, MAbs of the indicated specificities could be of value as prophylactic and/or therapeutic agents.
The binding of anti-O18 and anti-K5 MAbs to E. coli O18K5 was examined by using an enzyme-linked immunosorbent assay (ELISA) and flow cytometry. Functional activities of MAbs were studied by in vitro phagocytosis and in vivo protection. Before intraperitoneal (i.p.) challenge of mice, the bacteria were preincubated with MAbs. This procedure enabled comparison of in vitro binding of MAbs with protection results. Mice protection studies were also performed with prophylactically given MAbs.
MATERIALS AND METHODS
Bacterial strains. The E. coli strains used in this study (O18K5, O18K1, O18KϪ, O2K5, and O1K1) were all clinical isolates from the Utrecht University Hospital and have been previously described (10) . The bacteria were cultured at 37ЊC overnight either on blood agar plates or in Mueller-Hinton broth. Bacteria scraped from agar plates or centrifuged material collected from broth was spectrophotometrically adjusted in phosphate-buffered saline (PBS; pH 7.2) to an optical density that corresponded to a concentration of 2.5 ϫ 10 8 bacteria per ml. MAbs. MAbs were generated against the K5 capsule and O18 LPS of E. coli strains. Two independent immunization schedules were followed. BALB/c mice were injected i.p. with 10 8 gentamicin-treated bacteria from pools of several clinical E. coli isolates (either the O18KϪ or K5 serotype) four times at weekly intervals. A week after the last injection, sera obtained from ether-anesthetized mice were tested for the presence of antibodies against several O18KϪ or K5 E. coli isolates. When no agglutination of bacteria was observed, immunization was continued for another 4 weeks, using the same protocol. For the O18KϪ immunization, still another 4 weeks of immunization was necessary to obtain antibodies against all of the O18KϪ isolates.
After a 1-month rest, an intravenous (i.v.) booster of a mixture of three clinical isolates of the desired serotype containing 10 8 gentamicin-treated bacteria was given. Spleen cells were collected 3 days after the booster and fused with the SP2/0 myeloma cell line, using electrofusion (31) . A fusion pulse of either 2 or 3 kV/cm was given with a duration of 10 s. Hybridoma supernatant fluids were assayed by agglutination to detect the presence of specific antibodies against either E. coli O18KϪ or E. coli K5. A hybridoma (89.65) producing MAbs that reacted with O18 isolates and a hybridoma (91.71) producing antibodies to K5 isolates were then selected. Both hybridomas produced MAbs of the immunoglobulin M (IgM) isotype, as determined by an isotype-specific ELISA. The amount of IgM in ascitic fluid was determined by using the same ELISA with a standard IgM preparation. Anti-Helicobacter IgM and anti-Campylobacter MAbs (unpublished results) were used as control MAbs. Ascitic fluid was used in both ELISA and animal protection studies. Purified serum-free MAbs were used for flow cytometry.
To obtain purified MAbs, hybridomas were cultured in protein-free medium without additional nutrients (Gibco BRL/Life Technologies, Gaithersburg, Md.) (30) . MAbs in hybridoma supernatants were precipitated by addition of ammonium sulfate. The serum-free MAbs were dissolved in PBS and stored at Ϫ20ЊC.
FITC labeling of MAbs. For use in flow cytometry, purified anti-K5 and anti-O18 MAbs were labeled with fluorescein isothiocyanate isomer I (FITC; Sigma Chemical Co., St. Louis, Mo.). This labeling was accomplished by mixing 1 ml of MAb with 100 l of FITC (1 mg/ml) dissolved in 0.1 M NaHCO 3 (pH 9.6) and rotating the mixture in the dark for 1 h. Subsequently, the mixtures were dialyzed against double-distilled water for 1 h and overnight against PBS.
ELISA. Each well of ELISA plates (Titertek; Flow Laboratories, McLean, Va.) was coated with 100 l of a suspension of 2.5 ϫ 10 8 CFU of bacteria per ml in PBS (pH 7.2). The plates were incubated for 1 h at 37ЊC and kept overnight at 4ЊC. The plates were then washed five times with water containing 0.05% Tween 20 (water-Tween). MAbs to be tested were serially diluted in PBS supplemented with 4% bovine serum albumin (BSA) (Organon Teknika, Boxtel, The Netherlands) and 0.05% Tween 20; 50 l of diluted MAb was then added to each well. The plates were incubated at 37ЊC for 1 h and then washed five times with water-Tween. The horseradish peroxidase-coupled goat anti-mouse IgM, specific for heavy chains, was added in a 1:5,000 dilution (Southern Biotechnology Associates, Birmingham, Ala.) in 50 l of PBS with 1% BSA and 0.05% Tween 20. After a 1-h incubation at 37ЊC and five washings with water-Tween 20, the substrate, tetramethylbenzidine (10 g/ml; Sigma) with urea peroxide (20 mg/ml; Organon Teknika) in acetate buffer (1.1 M, pH 6.0), was added (50 l per well). After 10 min, the reaction was stopped by adding 50 l of 2 N H 2 SO 4 . The extinction was measured at 450 nm with an automated photometer (Titertek Multiskan; Flow Laboratories). Double immunofluorescence. Bacteria from a blood agar plate were spectrophotometrically adjusted to a concentration of 10 8 CFU per ml, and 100 l of this suspension was incubated with either unlabeled anti-O18 MAb (10 g/ml) or anti-K5 MAb (30 g/ml) under continuous shaking for 30 min at 4ЊC. To remove unbound MAb, bacterial suspensions were then washed twice with gelatin Hanks' balanced salt solution and incubated with 100 l of phycoerythrin (PE)-labeled goat anti-mouse Ig (10 g/ml; Southern Biotechnology Associates) under continuous shaking for 30 min at 4ЊC. After two washings to remove free PE-labeled goat anti-mouse Ig, the bacteria were incubated with either 100 l of FITClabeled anti-K5 MAb (30 g/ml) or FITC-labeled anti-O18 MAb (10 g/ml) under continuous shaking for 30 min at 4ЊC.
After two further washings to remove free FITC-labeled MAb, the bacteria were suspended in 0.5 ml of PBS. Samples were analyzed for fluorescence emission in a FACScan flow cytometer (Becton Dickinson Immunocytochemistry Systems, Mountain View, Calif.); in each sample, 10,000 bacteria were measured. Forward-and side-scatter parameters were optimized to exclude cell debris, large bacterial aggregates, and electronic background noise.
Isolation of human PMN. Human polymorphonuclear leukocytes (PMN) were isolated, using heparin-containing tubes (Becton Dickinson), from peripheral blood of healthy volunteers. A volume of 10 ml of blood was diluted with 10 ml of PBS (pH 7.4) and layered on a Ficoll-Histopaque gradient consisting of 10 ml of Ficoll-Paque (Pharmacia, Uppsala, Sweden) on top of 12 ml of Histopaque (density, 1.119 g/ml; Sigma Diagnostics, St. Louis, Mo.). After centrifugation at 400 ϫ g for 20 min at room temperature, PMN were collected from the upper part of the Histopaque, and ice-cold RPMI containing 0.1% gelatin (RPMIgelatin) was added. Cells were centrifuged at 250 ϫ g, and the residual erythrocytes were lysed by resuspending the cells in 9 ml of ice-cold distilled water. After 1 min, the cell suspension was made isotonic with concentrated PBS, and RPMIgelatin was added. PMN were centrifuged and resuspended in RPMI at 10 7 /ml. The purity and viability of the PMN were more than 95%.
J774 cell line. The mouse macrophage cell line J744A.1 (26) was used for phagocytosis. J744 cells were grown in a 5% CO 2 humidified atmosphere in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum, gentamicin (10 g/ml), and glutamine (4 mM). For the phagocytosis assay, cells were maintained for 3 days in culture (viability, Ͼ90%), washed once with PBS, and resuspended at a concentration of 10 7 /ml. The viability of the cells used in the experiments was always greater than 95% as determined by trypan blue exclusion.
Phagocytosis assay. Bacteria were labeled with FITC by adding 0.1 mg of FITC per ml dissolved in 0.1 M NaHCO 3 buffer and rotating the mixture for 1 h at 37ЊC. Bacteria were washed twice with PBS to remove free FITC and adjusted to 2.5 ϫ 10 8 CFU of bacteria per ml. From this suspension, 100 l was incubated with 100 l of purified MAb for 30 min in a 37ЊC shaking water bath. After two washings, 100 l of 0.2% human pooled serum or 0.2% mouse pooled serum, as a complement source, was added, and the mixture was incubated for another 20 min in a 37ЊC shaking water bath. Subsequently, human PMN or J774 cells (100 l of 10 7 cells per ml) were added and incubated for 12 min in a 37ЊC shaking water bath. Phagocytosis was stopped by adding ice-cold PBS. The fluorescence intensity of 10,000 PMN was measured in a flow cytometer by using a live gate, thereby excluding the measurement of fluorescent bacteria not associated with PMN. The fluorescence intensity of J774 cells was measured without a live gate. The fluorescent PMN or J774 cells were considered to be associated with FITC-labeled bacteria (1, 2, 29) . The total mean fluorescence of the cells was used as a measure for both uptake and binding of bacteria by PMN and referred to as phagocytosis. The mean fluorescence ratio was calculated to compare experiments from different days with each other; the mean fluorescence of the human PMN or J774 cells opsonized with MAbs was divided by the mean fluorescence of cells without MAbs.
Mice. Female BALB/c mice, 6 to 8 weeks old, were obtained from the Utrecht University animal facilities.
Animal protection studies. To determine the 50% lethal dose (LD 50 ) of E. coli O18K5, five groups of six mice were inoculated i.p. with either 10 5 , 10 6 , 10 7 , 10 8 , or 10 9 CFU of E. coli O18K5 in 0.5 ml of PBS (pH 7.2). The LD 50 was calculated by the method of Reed and Muench (27) and shown to be 2 ϫ 10 7 CFU/ml. For protection experiments, mice were inoculated with 0.5 ml of a mixture of MAb and 3 LD 50 s of E. coli O18K5. Before administration, this mixture was preincubated for 30 min at 37ЊC. Prophylactically, equal doses of MAbs were administered i.p. and i.v. 1 h before i.p. injection of 3 LD 50 s of E. coli O18K5. Deaths occurred generally within 24 h. Survival was recorded for 7 days.
Determination of TNF levels. Blood was obtained from ether-anesthetized mice by orbital puncture 90 min after challenge, and serum tumor necrosis factor (TNF) levels were determined by using the TNF-sensitive murine fibroblast cell line L-929. Logarithmically growing L cells were treated with trypsin, suspended in Dulbecco's modified Eagle's medium with fetal calf serum, seeded in microtiter wells of 96-well plates at a density of 2 ϫ 10 4 cells per 100 l, and incubated for 18 h at 37ЊC. Samples of TNF-containing sera were serially diluted (1/10, 1/20. . . .1/1,280), and 50 l of each dilution was then mixed with 50 l of Dulbecco's modified Eagle's medium-fetal calf serum supplemented with actinomycin D to a final concentration of 2 g/ml. L-cell monolayers incubated with medium only were used as controls for unlysed (0%) and completely lysed (100%) cells. Complete lysis was established by treating cells with 800 pg of human TNF per ml. A human TNF-␣ standard (National Institute for Biological Standards and Control, Hertfordshire, England) was included. After an 18-h incubation period, the plates were fixed for 15 min with 2.5% glutaraldehyde and washed with water. The residual cells were then stained with methylene blue (0.05%) for 30 min. After washing, the dye was solubilized in 100 l of 0.33 N HCl, and absorbance was measured at 595 nm with human TNF-incubated cells as a blank. The 50% lysis point for every sample was calculated from the linear part of the lysis curve. The TNF content (picograms per milliliter) for each sample was also calculated.
Statistical analysis. The chi-square test was applied to determine significant differences in survival between treatment groups. The Mann-Whitney test was applied to determine significant differences in TNF levels among mice from different treatment groups.
RESULTS
Antigen binding activity. The specificities of the anti-K5 and anti-O18 MAbs were determined with ELISA (results not shown). Serial dilutions of each IgM MAb were tested on ELISA plates coated with E. coli O1K1, O18K1, O2K5, or O18K5. The reactivity of the anti-K5 and anti-O18 MAbs to E. coli O1K1 did not differ from the reactivity of the negative control MAb. The anti-O18 MAb bound very well to E. coli O18K1. In contrast, the reactivity of anti-K5 MAb against E. coli O18K1 did not differ from that of the negative control MAb. A similar result was obtained for the anti-K5 MAb against E. coli O2K5. Thus, the anti-K5 MAb reacts only with the K5 capsule and the anti-O18 MAb reacts only with the O18 antigen.
To investigate whether the anti-K5 and anti-O18 MAbs detect the same individual E. coli O18K5 cell, double-immunofluorescence experiments were performed. To demonstrate double binding, one MAb was directly labeled with FITC and the other was detected by using a PE-labeled goat anti-mouse Ig. E. coli O18K5 from blood agar was incubated sequentially with the two different MAbs. Double-fluorescing bacteria indicated binding of both MAbs to individual bacteria (Fig. 1A) . Arbitrarily by immunofluorescence, three subpopulations of bacteria could be distinguished: one population that only The results also suggested a minor population to which neither MAb bound. In Table 1 , the percentages of the different populations that could be discriminated by flow cytometry are shown for three consecutive experiments. In experiments 1 and 2, the anti-K5 MAb stained the largest proportion of the bacterial population, while in experiment 3, the population of double-stained bacteria was the greatest. As a control for nonspecific staining in each experiment, several serotypes of E. coli strains were tested. E. coli O1K1, O18K1, O18KϪ, and O2K5 were sequentially incubated with the anti-K5 MAb and a PElabeled goat anti-mouse Ig and then stained with the FITClabeled anti-O18 MAb (Fig. 1B to E) . No double fluorescence was detected for E. coli O1K1, O18K1, and O18KϪ, indicating again the specificity of the anti-O18 MAb for the O18 antigen and the specificity of the anti-K5 MAb for the K5 capsule. However, 10% of the E. coli O2K5 cells showed double immunofluorescence (Fig. 1E ). This could be due to the fact that the strains were first incubated with the anti-K5 MAb, which could induce agglutination of the strains. Thus, double immunofluorescence indicated that by use of both MAbs, the majority (94%) of the E. coli O18K5 cells were stained, whereas this was not the case with either MAb alone. Enhancement of phagocytosis by combinations of anti-K5 and anti-O18 MAbs. FITC-labeled bacteria were used to study the ability of purified anti-K5 and anti-O18 MAbs, either alone or in combination, to mediate phagocytosis of E. coli O18K5. These bacteria were opsonized with different concentrations of the purified IgM MAbs, and human or mouse pooled serum was added as a complement source. The PMN-or J774 cellassociated fluorescence was determined by flow cytometry. Figure 2A shows phagocytosis of E. coli O18K5 by human PMN. Either the anti-O18 or the anti-K5 MAb alone was able to enhance phagocytosis, although the anti-O18 MAb induced high phagocytosis at low concentrations and anti-K5 MAb was effective at higher concentrations. The combination of the anti-O18 and anti-K5 MAbs, however, enhanced phagocytosis by human PMN at a total MAb concentration of 10 g/ml (P Ͻ 0.02) compared with each MAb alone. Phagocytosis could not be measured when heat-inactivated serum was used (data not shown). Comparable results were obtained with E. coli O18K5 bacteria grown for 4 h in Mueller-Hinton broth (data not shown). This at least additive enhancement of phagocytosis for the combination compared with each MAb alone was also measured when mouse macrophage J774 cells were used (Fig.  2B ), although this difference did not reach statistical significance.
Mouse protection studies. The protective efficacy of the anti-K5 and anti-O18 MAbs, alone and in combination, was evaluated in a mouse infection model in which a MAb and three LD 50 s of E. coli O18K5 (6 ϫ 10 7 CFU) were incubated for 30 min at 37ЊC prior to i.p. injection. The survival rates in three consecutive experiments are given in Table 2 . In experiment 3, serum was obtained to determine TNF 90 min after challenge; the results of the TNF determination are included in Table 2 . The summarized survival rates of animals receiving either MAb alone were 4 of 18 (22%) and 1 of 18 (6%) for the anti-K5 and anti-O18 MAbs, respectively. The combination of two MAbs together, however, had a dramatic impact on survival: 100% of all infected animals survived, which corresponds to a significant reduction in mortality when compared with that observed with the anti-K5 MAb (P Ͻ 0.001) and the anti-O18 MAb (P Ͻ 0.001). Only two animals in the PBS control group and four in the control (anti-Helicobacter) MAb group survived. In experiment 3, the mean TNF levels in serum correlated with the mortality in the experiment (r ϭ 0.84) as well as with the cumulative mortality in every group (r ϭ 0.93). As also shown in Table 2 , only the mice that had received the combination of MAbs had relatively low levels of TNF in serum, even though these mice received a smaller amount of MAbs than did mice in other treatment groups. Moreover, the observed values are at least 20-fold lower (P Ͻ 0.02) than those from any other treatment group. In addition, we performed protection experiments in which MAbs were administered independently of the bacteria. Prophylactically, MAbs were given both i.p. and i.v., and 1 h later, E. coli O18K5 (3 LD 50 s) was injected by the i.p. route (Table 3) . In this experiment, both the anti-K5 MAb alone and the combination of the anti-O18 and anti-K5 MAbs produced survival of all of the mice. However, the mice that received the combination of the anti-O18 and anti-K5 MAbs had the lowest TNF levels of the groups tested.
DISCUSSION
This study describes the enhanced protection against an otherwise lethal i.p. challenge of mice with E. coli O18K5 by two IgM MAbs, one directed against LPS (O18) and the other directed against the capsule (K5). The specificities of these MAbs were demonstrated by ELISA (results not shown) and flow cytometry (Fig. 1) . The anti-O18 MAb bound only to O18 serotypes, and the anti-K5 MAb bound only to E. coli containing the K5 capsule.
Depending on environment and phase of growth, bacteria produce different amounts of capsular polysaccharides (32) . Using flow cytometry (11), we also found gradually different bindings of the anti-O18 and anti-K5 MAbs to the O18K5 strain, as indicated by single-and double-stained bacteria. Arbitrarily, three major antigenically different subpopulations (phenotypes) could be distinguished in E. coli O18K5 from blood agar plates. One of the subpopulations consisted of bacteria that seemingly bound exclusively the anti-O18 MAb and thus produced no or a very little amount of the K5 capsule. Alternatively, the epitope recognized by the anti-K5 MAb may be lost by a reduction in length of the repeating sugar units constituting the capsule. Another subpopulation of bacteria bound only the anti-K5 MAb, suggesting that they had a lot of capsule, which prevented the anti-O18 MAb from binding to the O18 LPS beneath the capsule. A third subpopulation of bacteria (53%; Fig. 1A ) possessed an intermediate amount of capsule because both MAbs could bind to these bacteria. There was, however, always a small percentage (about 6%; Fig.  1A ) of unstained particles which could be explained by electronic background noise, caused by submicrometer particles in the sheath fluid or scatters from optical components (22) . Alternatively, these unstained particles represent either mutants of the smooth O18 strain or serological variants of O18. Heterogeneity of bacterial cultures has also been described for E. coli O18KϪ strains. Two antigenically different subpopulations were detected with anti-O18 MAbs (20) . Two distinct subpopulations of E. coli O26:B6 identified on the basis of differential binding by a core-reactive MAb have been described (8) . Distinct phenotypes have also been identified for E. coli J5 (9), indicating heterogeneity for this strain. Thus, antigenic heterogeneity in bacterial cultures might be a phenomenon more common than generally appreciated.
In vitro phagocytosis of E. coli O18K5 opsonized with the anti-O18 MAb in combination with the anti-K5 MAb compared with either MAb alone mediated by mouse macrophage J774 cells or human PMN in the presence of complement was enhanced (Fig. 2) . This result strongly suggests that the mechanism of the in vivo enhanced protection mediated by the anti-O18 MAb in combination with the anti-K5 MAb (Table 2) is complement-dependent, antibody-mediated phagocytosis of the bacteria.
Although 3 LD 50 s of E. coli O18K5 turned out to contain 6 ϫ 10 7 bacteria, which is quite a large inoculum, this bacterial challenge is comparable to bacterial bolus infusions used in other animal models of infections (6) . Furthermore, the protection experiments suggest that both the K5 capsule and the O18 LPS contribute to the virulence of E. coli O18K5. In agreement with this suggestion, Cross et al. (4) found that the LD 50 of the O18K5-encapsulated parent was similar to that of its unencapsulated mutant. Both the K5 capsule and the O18 LPS are presumably capable of preventing antibody-independent classical pathway activation by shielding deeper structures of the cell membrane that are able to activate this pathway (16, 24) .
The protective capacity of anti-O18 antibodies has been described previously for neonatal rats (21, 23, 28) . However, in neonatal rats, the immune system has not been fully developed, while we used mice at ages of between 6 and 8 weeks with a normally developed immune system. Our results are in agreement with those of Kim et al. (17) , who described the enhanced protective efficacy of anti-K1 and anti-O18 MAbs in a rat O18K1 infection model. A total of 79% survived in the group receiving the combination, whereas only 25% survived in the groups receiving either MAb alone. Kim et al. (17) described enhanced phagocytosis of E. coli O18K1 mediated by either the anti-O18 or the anti-K1 MAb, in agreement with our results. However, the combination of both MAbs was not tested as we did in the present study.
The release of TNF in serum was measured 90 min after bacterial challenge, because it is known that 90 min after challenge the peak value is reached (6) . Preincubation of the bacterial inoculum with the combination of the anti-O18 and anti-K5 MAbs inhibited the release of TNF in serum, while neither antibody alone did so ( Table 2 ). The low TNF levels correlated with survival of the mice. The TNF levels in the group treated with both MAbs were lower than in the control groups. When prophylactically given the anti-O18 and anti-K5 MAbs, either alone or in combination, protected mice when the combination of the anti-O18 and anti-K5 MAbs was given but also when anti-K5 alone was given. However, prophylactically the combination of both MAbs significantly (P Ͻ 0.01) reduced the TNF levels compared with any other treatment group (Table 3) . This means that the protective mechanism acted very quickly. Probably, the release of LPS was prevented by rapid phagocytosis so that priming of sensitive cells for TNF e Mortality significantly less (P Ͻ 0.001) than that of groups receiving only the anti-K5 MAb and significantly less (P Ͻ 0.001) than that recorded for groups treated with the anti-O18 MAb alone.
f TNF level significantly lower (P Ͻ 0.02) than in any other group. Combination immunotherapy has also been described for other gram-negative bacteria. Cross et al. (5) used three antibodies to protect neutropenic rats against infection with Pseudomonas aeruginosa, which resulted in enhanced survival. The triple combination of a murine anti-Pseudomonas (IgG1) MAb, an anti-murine TNF-␣ MAb, and a rabbit polyclonal antiserum directed against J5 was most effective in this study.
In summary, the results of this study demonstrate that use of the combination of anti-K5 and anti-O18 MAbs resulted in significantly enhanced protection in our mouse model of bacterial peritonitis. Use of combinations of anticapsule and anti-LPS antibodies might prevent selection of either capsule-rich or capsule-deficient bacteria in vivo. Escaping bacteria may cause more serious disease. Therefore, combinations of two (or more) antibodies to different cell wall components may be more beneficial in preventing and treating infection than use of antibodies with a single specificity.
